Summary
CVS Health Corporation has announced the successful issuance and sale of a significant amount of junior subordinated notes, totaling $3.0 billion. This includes $2.25 billion in Series A Junior Subordinated Notes due 2055 with a 7.000% fixed-to-fixed rate, and $750 million in Series B Junior Subordinated Notes due 2054 with a 6.750% fixed-to-fixed rate. These notes were offered under the company's existing Form S-3ASR registration statement filed in May 2023. This debt issuance represents a strategic move by CVS Health to bolster its capital structure. The junior subordinated nature of these notes suggests they are intended to enhance the company's financial flexibility, potentially for future investments, acquisitions, or to manage existing debt obligations. Investors should note the specific interest rates and maturity dates, as well as the subordinated status which implies a higher risk profile compared to senior debt but offers a corresponding yield.
Key Highlights
- 1CVS Health issued $2.25 billion of 7.000% Series A Junior Subordinated Notes due 2055.
- 2CVS Health issued $750 million of 6.750% Series B Junior Subordinated Notes due 2054.
- 3Total aggregate principal amount of notes issued is $3.0 billion.
- 4The notes are junior subordinated, indicating a specific position in the capital structure.
- 5The issuance was conducted under the company's Form S-3ASR registration statement.
- 6The notes are governed by a Base Indenture and specific Supplemental Indentures.
- 7The company may issue additional subordinated debt securities under the Base Indenture.